{
    "Trade/Device Name(s)": [
        "Creatine Kinase-MB"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K162526",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003158"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHW"
    ],
    "Summary Letter Date": "March 3, 2017",
    "Summary Letter Received Date": "March 6, 2017",
    "Submission Date": "May 23, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatine kinase MB subunit (CK-MB)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-Heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Gel Separation tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "cobas c 501 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Photometric assay",
        "Antibody inhibition",
        "UV test"
    ],
    "Methodologies": [
        "Quantitative measurement of enzyme activity",
        "Two reagent assay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Creatine Kinase-MB photometric assay to quantitatively determine CK-MB in human serum and plasma using Roche/Hitachi cobas c systems",
    "Indications for Use Summary": "In-vitro quantitative determination of CK-MB catalytic activity in human serum and plasma on Roche/Hitachi cobas c systems, aiding diagnosis and treatment of myocardial infarction and muscle diseases such as Duchenne muscular dystrophy",
    "fda_folder": "Clinical Chemistry"
}